Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

Monte Rosa Therapeutics, Inc. (GLUE) vs Janux Therapeutics, Inc. (JANX)

Monte Rosa Therapeutics, Inc. and Janux Therapeutics, Inc. are both Biotechnology companies. Monte Rosa Therapeutics, Inc. and Janux Therapeutics, Inc. are of similar size ($1.0B and $999.9M). Janux Therapeutics, Inc. grew revenue faster over the last twelve months: 83.9% against −83.9%. Janux Therapeutics, Inc. has the higher net margin (−427.5% vs −560.9%) and the higher return on invested capital (0.00% vs 0.00%). Across the 14 metrics below, Janux Therapeutics, Inc. leads on 10 and Monte Rosa Therapeutics, Inc. on 4.

Valuation

Metric GLUE JANX Biotechnology median
P/E n/m n/m 7.88
P/S 41.58 42.74 11.47
P/B 2.45 1.11 2.52
Price to free cash flow n/m n/m 21.16
EV/EBITDA n/m n/m 0.74
EV/Sales 19.96 2.29 10.73
Earnings yield (14.95%) (10.06%) (28.84%)
Free cash flow yield (2.69%) (4.09%) (23.03%)

Profitability

Metric GLUE JANX Biotechnology median
Gross margin 100.00% 100.00% 65.16%
Operating margin (633.04%) (598.15%) 0.00%
Net margin (560.85%) (427.47%) 0.00%
Free cash flow margin (111.66%) (174.69%) 0.00%
Return on equity (42.66%) (10.70%) (57.72%)
Return on assets (30.67%) (10.06%) (49.22%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric GLUE JANX Biotechnology median
Revenue growth (TTM) (83.86%) 83.92% 5.64%
EPS growth (last fiscal year) 53.06% (42.97%) —
Revenue growth, 5-year CAGR — — 8.40%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric GLUE JANX Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 10.58 16.35 4.73
Net debt to EBITDA 8.22 5.58 0.96

Dividend

Metric GLUE JANX Biotechnology median
Dividend yield — — 2.10%
Payout ratio 0.00 0.00 0.00

Size

Metric GLUE JANX Biotechnology median
Market cap 999.87m 1.02b 162.10m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack